PHILADELPHIA, Sept. 15, 2026 /PRNewswire/ — Berger Montague PC, a leading national plaintiffs’ law firm, announces a class action lawsuit against Beta Bionics, Inc. (NASDAQ: BBNX) (“Beta Bionics” or the “Company”) on behalf of investors who purchased or acquired Beta Bionics securities during the period from July 30, 2025 through February 24, 2026 (the “Class Period”). The deadline to apply for lead plaintiff is November 3, 2026.
Q&A
What is this lawsuit about?
This lawsuit concerns whether Beta Bionics and certain of its officers misled investors about the Company’s automated insulin delivery system, known as the iLet Bionic Pancreas insulin pump, the Company’s sole commercialized product.
According to the complaint, after the Company disclosed that it had received a Form 483 notice from the FDA following an inspection of its manufacturing facility, Beta Bionics repeatedly assured investors that the FDA’s observations concerned only its handling of customer complaints, as opposed to any underlying safety or efficacy issue with the iLet device.
However, the suit alleges that the FDA’s findings implicated the Company’s quality management system, its investigation and correction of device malfunctions, and its risk analysis for the device itself. Moreover, according to the complaint, the Company had failed to report serious injuries.
As this information was revealed to investors, the price of Beta Bionics common stock declined, and investors suffered losses.
Who is Beta Bionics?
Beta Bionics, based in Irvine, Calif., is a medical device company that develops and markets the iLet Bionic Pancreas, an automated insulin delivery system for people with diabetes.
What do I need to do?
If you are a Beta Bionics investor and would like to learn more about this action, CLICK HERE or please contact Berger Montague: Andrew Abramowitz at aabramowitz@bergermontague.com or (215) 875-3015 or Caitlin Adorni at cadorni@bergermontague.com or (267) 764-4865 or visit our website.
What is the Beta Bionics lead plaintiff deadline?
The deadline to apply for lead plaintiff appointment is November 3, 2026. This deadline applies only to investors seeking to serve as lead plaintiff. Class members who do not apply may still participate in any recovery without taking action before this date.
About Berger Montague
Berger Montague is one of the nation’s preeminent law firms focusing on complex civil litigation, class actions, and mass torts in federal and state courts throughout the United States. With more than $2.4 billion in 2025 post-trial judgments alone, the Firm is a leader in the fields of complex litigation, antitrust, consumer protection, defective products, environmental law, employment law, securities, and whistleblower cases, among many other practice areas. For over 55 years, Berger Montague has played leading roles in precedent-setting cases and has recovered over $50 billion for its clients and the classes they have represented. Berger Montague is headquartered in Philadelphia and has offices in Chicago; Malvern, PA; Minneapolis; San Diego; San Francisco; Toronto, Canada; Washington, D.C., and Wilmington, DE.
For more information or to discuss your rights, please contact:
Andrew Abramowitz
Berger Montague
(215) 875-3015
aabramowitz@bergermontague.com
Caitlin Adorni
Berger Montague
(267) 764-4865
cadorni@bergermontague.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/attention-nasdaq-bbnx-investors-contact-berger-montague-about-a-beta-bionics-inc-class-action-lawsuit-302877009.html
SOURCE Berger Montague
